Cover Image

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma

Background - The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30%. This study aimed to investigate the efficacy of cemiplimab as first-line or second-line treatment of BCC in a German...

Full description

Saved in:
Bibliographic Details
Main Authors: DeTemple, Viola (Author) , Kaatz, Martin (Author) , Stockfleth, Eggert (Author) , Scheel, Christina (Author) , Angela, Yenny (Author) , Gutzmer, Ralf (Author) , Leiter, Ulrike (Author) , Meier, Friedegund (Author) , Schadendorf, Dirk (Author) , Livingstone, Elisabeth (Author) , Gebhardt, Christoffer (Author) , Wasielewski, Imke von (Author) , Weichenthal, Michael (Author) , Mohr, Peter (Author) , Hassel, Jessica C. (Author) , Pföhler, Claudia (Author) , Simon, Jan Christoph (Author) , Jochims, Franziska (Author) , Terheyden, Patrick (Author) , Ulrich, Jens (Author) , Haferkamp, Sebastian (Author) , Drexler, Konstantin (Author) , Schilling, Bastian (Author) , Glutsch, Valerie (Author) , Heinzerling, Lucie (Author) , Berking, Carola (Author) , Ugurel, Selma (Author) , Tomsitz, Dirk (Author)
Format: Article (Journal)
Language:English
Published: 25 July 2025
In: European journal of cancer
Year: 2025, Volume: 225, Pages: 1-7
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115590
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2025.115590
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804925003727
Get full text
Author Notes:Viola K. DeTemple, Martin Kaatz, Eggert Stockfleth, Christina Scheel, Yenny Angela, Ralf Gutzmer, Ulrike Leiter, Friedegund Meier, Dirk Schadendorf, Elisabeth Livingstone, Christoffer Gebhardt, Imke von Wasielewski, Michael Weichenthal, Peter Mohr, Jessica Hassel, Claudia Pföhler, Jan Christoph Simon, Franziska Jochims, Patrick Terheyden, Jens Ulrich, Sebastian Haferkamp, Konstantin Drexler, Bastian Schilling, Valerie Glutsch, Lucie Heinzerling, Carola Berking, Selma Ugurel, Dirk Tomsitz
Description
Summary:Background - The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30%. This study aimed to investigate the efficacy of cemiplimab as first-line or second-line treatment of BCC in a German real-world patient cohort. - Methods - Patients with histologically confirmed locally advanced or metastatic BCC who were treated with cemiplimab were retrospectively identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Therapy outcome was compared between patients receiving first-line cemiplimab and patients treated with cemiplimab in second-line. - Results - 37 patients from 17 skin cancer centers were identified who received cemiplimab. The median follow-up after start of any first-line treatment was 37.1 months, and 17.9 months after initiation of any cemiplimab treatment. Patients who received first-line cemiplimab (n=8) had an ORR of 62.5%, compared to an ORR of 31.0% for patients who received second-line cemiplimab (n=29); Median PFS was 19.8 months for first-line cemiplimab and 5.3 months for second-line cemiplimab. Reinduction with HHIs after progression on second-line cemiplimab resulted in an ORR of 20.0% and a median PFS of 3.8 months. - Conclusion - We demonstrate a comparable outcome for cemiplimab as second-line treatment of BCC in our real-world patient cohort as reported in previous registration studies. Additionally, we found a trend for a more favorable outcome in first-line therapy, suggesting a rationale to further investigate cemiplimab as first-line treatment of advanced BCC.
Item Description:Online verfügbar: 24. Juni 2025, Artikelversion: 27. Juni 2025
Gesehen am 06.03.2026
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115590

Similar Items